Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

RINGSIDE part B

110 evidence topics · 25 sources

Objective
Location and study date
Registry status and dates for the combined Part A, Part B, and open-label extension record
Study characteristicQuoted record
Overall status“Active, not recruiting”
Study start (actual)“2021-09-01”
Primary completion (actual)“2025-12-03”
Study completion (estimated)“2026-12”
Number of locations“This study has 53 locations”
Study design
Eligibility criteria
Exclusion criteria for Parts A and B in the registry record
Treatment
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, tumor characteristics, and prior therapy
Characteristic, n (%)Varegacestat (n=79)Placebo (n=77)
Median age (range), years“42.0 (18–66)”“39.0 (20–69)”
Male“26 (32.9)”“29 (37.7)”
Female“53 (67.1)”“48 (62.3)”
Premenopausal“36 (45.6)”“38 (49.4)”
Target tumor location: extra-abdominal“60 (75.9)”“49 (63.6)”
Target tumor location: intra-abdominal“19 (24.1)”“28 (36.4)”
Medical history of FAP“7 (8.9)”“8 (10.4)”
Median target tumor size per RECIST (range), mm“75.1 (18.0, 244.9)”“84.8 (21.3, 666.3)”
Any prior therapy“52 (65.8)”“60 (77.9)”
Prior surgery“24 (30.4)”“33 (42.9)”
Prior radiation therapy“8 (10.1)”“12 (15.6)”
Prior systemic therapy“43 (54.4)”“46 (59.7)”
Prior systemic therapies: 0 lines“36 (45.6)”“31 (40.3)”
Prior systemic therapies: 1 line“25 (31.6)”“22 (28.6)”
Prior systemic therapies: 2 or more lines“18 (22.8)”“24 (31.2)”
Premenopausal women as a proportion of female participants
CharacteristicVaregacestat (n=79)Placebo (n=77)
Premenopausal, n/N of female participants (%)“36/53 (67.9)”“38/48 (79.2)”
Efficacy results
RINGSIDE phase 3 trial outcomes table
OutcomeVAR (n=79)PBO (n=77)HR (95% CI) or Difference; P value
Median PFS (95% CI), radiographic, months“NE (NE, NE)”“24.9 (13.8, NE)”“0.16 (0.07, 0.38); P<0.0001”
Confirmed ORR, n (%)“44 (55.7)”“7 (9.1)”“P<0.0001”
TV change (cm3) at Week 24, LS mean (SE)“-109.6 (40.64)”“122.8 (42.72)”“-232.4 (57.39); P<0.0001”
WPI (pain) change at Week 12, LS mean (SE)“-2.24 (0.27)”“0.18 (0.27)”“-2.42 (0.37); P<0.0001”
Median best % change in TV (not alpha-controlled)“-83.4”“11.3”
Landmark progression-free survival rates at 1 and 2 years
Objective response, time to response, and best overall response
OutcomeVaregacestat (n=79)Placebo (n=77)
Objective response rate, n (%) [95% CI]“44 (55.7) [44.1, 66.9]”“7 (9.1) [3.7, 17.8]”
Time to objective response (months), median (range)“8.2 (2.6–28.0)”“16.7 (8.1–30.2)”
Duration of response (months), median (95% CI), Kaplan-Meier estimate“NE (NE, NE)”“NE (NE, NE)”
Complete response (CR)“3 (3.8)”“1 (1.3)”
Partial response (PR)“41 (51.9)”“6 (7.8)”
Stable disease (SD)“32 (40.5)”“59 (76.6)”
Progressive disease (PD)“0”“10 (13.0)”
Not available“3 (3.8)”“1 (1.3)”
Health-related quality of life and patient-reported outcomes
Safety results
Adverse events reported in 25% or more of either arm, ASCO 2026 presentation
Adverse event (MedDRA preferred term), n (%)Varegacestat any gradeVaregacestat grade 3+Placebo any gradePlacebo grade 3+
Any adverse event“79 (100)”“45 (57)”“70 (91)”“13 (17)”
Diarrhea“65 (82)”“8 (10.1)”“21 (27)”“0”
Fatigue“35 (44)”“1 (1.3)”“18 (23)”“2 (2.6)”
Rash“34 (43)”“2 (2.5)”“9 (12)”“0”
Nausea“28 (35)”“0”“20 (26)”“0”
Cough“27 (34)”“0”“4 (5)”“0”
Hypophosphatemia“27 (34)”“1 (1.3)”“2 (3)”“0”
Alopecia“26 (33)”“0”“3 (4)”“0”
Dry mouth“24 (30)”“0”“5 (7)”“0”
Hair color changes“20 (25)”“0”“0”“0”
Pruritus“20 (25)”“0”“4 (5)”“0”
Rash maculo-papular“20 (25)”“1 (1.3)”“1 (1)”“0”
Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster
Adverse event (MedDRA preferred term), n (%)Varegacestat any gradeVaregacestat grade ≥3Placebo any gradePlacebo grade ≥3
Any adverse event“79 (100)”“45 (57)”“70 (91)”“13 (17)”
Diarrhea“65 (82)”“8 (10)”“21 (27)”“0”
Fatigue“35 (44)”“1 (1)”“18 (23)”“2 (2.6)”
Rash“34 (43)”“2 (3)”“9 (12)”“0”
Nausea“28 (35)”“0”“20 (26)”“0”
Cough“27 (34)”“0”“4 (5)”“0”
Hypophosphatemia“27 (34)”“1 (1)”“2 (3)”“0”
Alopecia“26 (33)”“0”“3 (4)”“0”
Dry mouth“24 (30)”“0”“5 (7)”“0”
Hair color changes“20 (25)”“0”“0”“0”
Pruritus“20 (25)”“0”“4 (5)”“0”
Rash maculo-papular“20 (25)”“1 (1)”“1 (1)”“0”
ALT increase“18 (23)”“3 (4)”“4 (5)”“0”
AST increase“18 (23)”“2 (3)”“2 (3)”“0”
Amenorrhea“17 (22)”“0”“2 (3)”“0”
Upper respiratory tract infection“17 (22)”“0”“5 (7)”“0”
Vomiting“16 (20)”“0”“6 (8)”“0”
Frequently reported adverse events as grouped terms, with median time to first onset
Adverse event, n (%)Varegacestat all gradesVaregacestat median time to onset (days)Varegacestat grade ≥3Placebo all gradesPlacebo median time to onset (days)Placebo grade ≥3
Diarrhea“65 (82.3)”“14.0”“8 (10.1)”“21 (27.3)”“21.0”“0”
Rash (grouped term)“56 (70.9)”“24.0”“4 (5.1)”“13 (16.9)”“69.0”“0”
Fatigue (grouped term)“46 (58.2)”“27.5”“1 (1.3)”“24 (31.2)”“19.0”“2 (2.6)”
Hair follicle AEs (grouped term)“32 (40.5)”“59.0”“2 (2.5)”“3 (3.9)”“70.0”“0”
Cough (grouped term)“31 (39.2)”“16.0”“1 (1.3)”“5 (6.5)”“198.0”“0”
Nausea“28 (35.4)”“8.0”“0”“20 (26.0)”“7.5”“0”
Hypophosphatemia“27 (34.2)”“29.0”“1 (1.3)”“2 (2.6)”“49.5”“0”
Upper respiratory infection (grouped term)“27 (34.2)”“46.0”“0”“6 (7.8)”“136.5”“0”
Dry mouth“24 (30.4)”“13.0”“0”“5 (6.5)”“8.0”“0”
Hair color changes“20 (25.3)”“60.5”“0”“0”“0”
Ovarian toxicity (grouped term; percentage of the whole population)“20 (25.3)”“56.5”“0”“2 (2.6)”“41.5”“0”
Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma
Adverse event of interestVaregacestat grade 1Varegacestat grade 2Varegacestat grade 3Placebo grade 1Placebo grade 2Placebo grade 3
Diarrhea“43.0%”“29.1%”“10.1%”“23.4%”“3.9%”
Rash (grouped terms)“36.7%”“29.1%”“5.1%”“14.3%”“2.6%”
Ovarian toxicity“25.3%”“2.6%”
Squamous cell carcinoma and keratoacanthoma“1.3%”“6.3%”“1.3%”“1.3%”
Elevated liver enzymes (ALT or AST grade 2 or higher)“3.8%”“3.8%”“2.6%”
Adverse events leading to dose interruption
Preferred term, n (%)Varegacestat (n=79)Placebo (n=77)
Diarrhea“9 (11.4)”“1 (1.3)”
Fatigue“6 (7.6)”“0”
Rash“6 (7.6)”“0”
Vomiting“5 (6.3)”“1 (1.3)”
ALT increased“4 (5.1)”“2 (2.6)”
Pyrexia“4 (5.1)”“1 (1.3)”
Study limitations
Summary
  • Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
  • The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
  • Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
  • At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
  • The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
  • Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
  • Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
  • The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
  • Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.